eukaryotic translation initiation factor 3 subunit C likeGenealiases: []
Q-omics provides the consensus-scored EIF3CL profile across patient tissues and cancer cell-line models. EIF3CL expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, EIF3CL is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, EIF3CL RNA expression shows 14,272 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, and TGCT as cancer lineages where EIF3CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3CL survival associations across molecular data types. EIF3CL RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3CL RNA expression–survival associations across cancer types. High EIF3CL expression shows unfavorable associations in LIHC, UCS, LUAD and BLCA, but favorable associations in LUSC and SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for EIF3CL RNA expression.
This table summarizes EIF3CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3CL shows higher tumor expression in LIHC, HNSC, KIRC, LUSC, CHOL and BLCA. The LIHC box plot shows higher EIF3CL RNA expression in tumor versus normal tissue (log2 FC = +0.145, t-test p < 0.001).
This table shows molecular features associated with EIF3CL in patient tissues and cancer cell lines. In patient samples, EIF3CL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF3CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
